Department of Interventional Radiology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China.
Interventional Institute of Zhengzhou University, Zhengzhou, China.
Elife. 2022 Nov 8;11:e81114. doi: 10.7554/eLife.81114.
Molecular subtypes of colorectal cancer (CRC) are currently identified via the snapshot transcriptional profiles, largely ignoring the dynamic changes of gene expressions. Conversely, biological networks remain relatively stable irrespective of time and condition. Here, we introduce an individual-specific gene interaction perturbation network-based (GIN) approach and identify six GIN subtypes (GINS1-6) with distinguishing features: (i) GINS1 (proliferative, 24%34%), elevated proliferative activity, high tumor purity, immune-desert, mutations, and immunotherapeutic resistance; (ii) GINS2 (stromal-rich, 14%22%), abundant fibroblasts, immune-suppressed, stem-cell-like, mutations, unfavorable prognosis, high potential of recurrence and metastasis, immunotherapeutic resistance, and sensitive to fluorouracil-based chemotherapy; (iii) GINS3 (-inactivated, 13%20%), high tumor purity, immune-desert, activation of and ephrin receptors, chromosomal instability (CIN), fewer mutations, methylation, immunotherapeutic resistance, and sensitive to cetuximab and bevacizumab; (iv) GINS4 (mixed, 10%19%), moderate level of stromal and immune activities, transit-amplifying-like, and methylation; (v) GINS5 (immune-activated, 12%24%), stronger immune activation, plentiful tumor mutation and neoantigen burden, microsatellite instability and high CpG island methylator phenotype, mutations, favorable prognosis, and sensitive to immunotherapy and inhibitors; (vi) GINS6, (metabolic, 5%8%), accumulated fatty acids, enterocyte-like, and activity. Overall, the novel high-resolution taxonomy derived from an interactome perspective could facilitate more effective management of CRC patients.
结直肠癌(CRC)的分子亚型目前是通过瞬时转录谱来鉴定的,在很大程度上忽略了基因表达的动态变化。相反,生物网络无论时间和条件如何相对稳定。在这里,我们引入了一种基于个体特异性基因互作扰动网络(GIN)的方法,并确定了六个具有区别特征的 GIN 亚型(GINS1-6):(i)GINS1(增殖型,24%34%),具有较高的增殖活性、高肿瘤纯度、免疫荒漠、突变和免疫治疗抵抗;(ii)GINS2(基质丰富型,14%22%),富含成纤维细胞、免疫抑制、干细胞样、突变、不良预后、高复发和转移潜力、免疫治疗抵抗以及对氟尿嘧啶为基础的化疗敏感;(iii)GINS3(失活型,13%20%),高肿瘤纯度、免疫荒漠、激活 EphA 受体和 Ephrin 受体、染色体不稳定(CIN)、较少的突变、甲基化、免疫治疗抵抗以及对西妥昔单抗和贝伐珠单抗敏感;(iv)GINS4(混合型,10%19%),中等水平的基质和免疫活性、过渡扩增样、以及甲基化;(v)GINS5(免疫激活型,12%24%),更强的免疫激活、丰富的肿瘤突变和新抗原负荷、微卫星不稳定和高 CpG 岛甲基化表型、突变、良好的预后以及对免疫治疗和 PARP 抑制剂敏感;(vi)GINS6(代谢型,5%8%),堆积的脂肪酸、肠细胞样、以及代谢活性。总的来说,从互作组的角度得出的新的高分辨率分类法可以促进更有效地管理 CRC 患者。